Search Results

290 articles with title/keywords/abstract containing Postmarketing-surveillance

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
modify search
Display per page 

Prevnar batch suspended after three infant deaths

Source: Reactions, Volume 1, Number 1278, 2009-11-14 , pp. 2-2(1)

Publisher: Adis International

Natalizumab doing well outside phase III trials

Source: Reactions, Volume 1, Number 1275, 2009-10-24 , pp. 5-5(1)

Publisher: Adis International

Industry improves on-time performance of PMS studies

Source: Reactions, Volume 1, Number 1269, 2009-09-12 , pp. 2-2(1)

Publisher: Adis International

Tradition rules in signal detection?

Source: Reactions, Volume 1, Number 1263, 2009-08-01 , pp. 1-1(1)

Publisher: Adis International

Ezetimibe/HMG-CoA reductase inhibitors: Amyotrophic lateral sclerosis-like conditions: 10 case reports

Source: Reactions, Volume 1, Number 1264, 2009-08-08 , pp. 17-18(2)

Publisher: Adis International

Injection-site reactions were the most common adverse event (AE) observed during a Japanese postmarketing surveillance study of etanercept

Source: Reactions, Volume 1, Number 1258, 2009-06-27 , pp. 3-3(1)

Publisher: Adis International

The reporting rate of venous thromboembolism (VTE) for myelodysplastic syndrome (MDS) patients receiving lenalidomide was low

Source: Reactions, Volume 1, Number 1244, 2009-03-21 , pp. 3-3(1)

Publisher: Adis International

Majority of post-VZV vaccination rashes not serious

Source: Reactions, Volume 1, Number 1229, 2008-11-22 , pp. 2-2(1)

Publisher: Adis International

Population-based outcome studies "a natural step"

Source: Inpharma, Volume 1, Number 1665, 2008-11-22 , pp. 2-2(1)

Publisher: Adis International

EMEA recommends suspending Acomplia

Source: Reactions, Volume 1, Number 1226, 2008-11-01 , pp. 3-3(1)

Publisher: Adis International

EMEA recommends suspending Acomplia

Source: Inpharma, Volume 1, Number 1662, 2008-11-01 , pp. 22-22(1)

Publisher: Adis International

Third report of Tysabri-linked PML in commercial setting

Source: Reactions, Volume 1, Number 1227, 2008-11-08 , pp. 3-3(1)

Publisher: Adis International

Third report of Tysabri-linked PML in commercial setting

Source: Inpharma, Volume 1, Number 1663, 2008-11-08 , pp. 20-20(1)

Publisher: Adis International

A chance to improve pharmacovigilance

Source: Reactions, Volume 1, Number 1218, 2008-09-06 , pp. 2-2(1)

Publisher: Adis International

Postmarketing study commitments are becoming routine in the US, Europe and Japan

Source: Reactions, Volume 1, Number 1214, 2008-08-09 , pp. 4-4(1)

Publisher: Adis International

All patients with multiple sclerosis who have completed mitoxantrone treatment should be monitored for late cardiac toxicity

Source: Reactions, Volume 1, Number 1214, 2008-08-09 , pp. 4-4(1)

Publisher: Adis International

Tysabri-linked PML: report of two cases in commercial setting

Source: Reactions, Volume 1, Number 1214, 2008-08-09 , pp. 4-4(1)

Publisher: Adis International

The Canadian government plans to invest $Can1 million this year to aid the establishment of the Drug Safety and Effectiveness Network

Source: Reactions, Volume 1, Number 1212, 2008-07-26 , pp. 2-2(1)

Publisher: Adis International

CellCept label updated with PML safety information

Source: Reactions, Volume 1, Number 1209, 2008-07-05 , pp. 3-3(1)

Publisher: Adis International

Radiation recall with pemetrexed

Source: Reactions, Volume 1, Number 1207, 2008-06-21 , pp. 3-3(1)

Publisher: Adis International

modify search
Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A